Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Maintenance After Hyperfractionated Radiotherapy and Chemotherapy in Limited-stage SCLC
ChiCTR2400082364Phase 2Not yet recruiting
- Sponsor
- Beidahuang Group General Hospital
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Beidahuang Group General Hospital. Primary endpoints: Safety and 12-month progression-free survival rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400082364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082364.